in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a ...
Future Oncol. 2012;8(9):1135-1147. Follow-up, initiation, execution and tailoring of treatment in case of recurrence of ovarian cancer have to take into account evidence-based guidelines and the ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...
The therapeutic landscape in recurrent ovarian cancer is characterized by well-established strategies, a number of concepts still lacking confirmation in prospective randomized trials and numerous ...
Carrie Regan, 41, went to the ER in 2023 because of stomach pain, which led to an ovarian cancer diagnosis. Regan is now in good health and is monitored for recurrence. She wants other women to be ...
Machine learning for epithelial ovarian cancer platinum resistance recurrence identification using routine clinical ... derived organoids (PDOs), platinum resistance, PARP inhibitors (PARPi), ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, that may be key in helping the immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback